Tests a drug-releasing stent for narrowed vertebral arteries
Tests a drug-releasing stent in adults with narrowed vertebral arteries.
Key facts
- Who runs it
- Nanfang Hospital, Southern Medical University
- Where
- Guangzhou, ChinaSee the site
- Trial code
- Registry title
- Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis
- Status
- Recruiting
- People taking part
- 144 people, planned
- Started
- 1 May 2022
- Expected to end
- 31 May 2029
- Type of study
- Interventional
- Treatments tested
- The drug-eluting stent
- Record updated
- 14 March 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with narrowing of a vertebral artery from atherosclerosis who have been prescribed a rapamycin drug-eluting vertebral artery stent. It watches how well the stent works in everyday care.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Narrowing of the vertebral artery caused by atherosclerosis, treated with a drug-eluting vertebral artery stent.
Main reasons for not taking part
- Cannot take dual antiplatelet therapy
- Severe bleeding or clotting problems, or active bleeding in the gut
- Heart attack or large stroke within the past 2 weeks
- Known reaction risk to heparin, rapamycin, anesthesia or contrast agents
- Life expectancy of less than 12 months
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age ≥ 18 years old, gender is not limited
- Patients with medically prescribed rapamycin drug-eluting vertebral artery stent systems
- Patients and family members fully understand the trial's purpose, voluntarily participate in the trial and sign the informed consent form
Who cannot take part
- With an aneurysm that cannot be treated earlier or simultaneously or is not suitable for surgery
- Previous myocardial infarction or large-scale cerebral infarction within 2 weeks
- Unable to receive dual antiplatelet therapy due to known disease, or severe coagulation abnormalities, severe infections that are not controlled, severe systemic disease, uncontrollable hypertension, and contraindicated for surgery
- Gastrointestinal disease with active bleeding
- Known contraindications to heparin, rapamycin, anesthesia, and contrast agents
- Life expectancy less than 12 months
- the investigator judged patients to be unsuitable for participation in this study
Where in China
- Nanfang Hospital of Southern Medical UniversityGuangzhou, ChinaContact: Zhong Ji, PHDTaking people
About the trial
What the trial wants to find out
This is a prospective, multi-center, open-access, single-arm trial to observe the real-world clinical efficacy of drug-eluting vertebral artery stenting system treatment for Atherosclerotic Vertebral Arteries Stenosis. Patients will be followed at 30 days, 6, and 12 months post-procedure and annually for 1 year within 3 years.
The group in the trial
- Patients with vertebral atherosclerotic stenosis requiring stent implantationTreatment being tested
Referring to "the 2015 Chinese Guidelines for Endovascular Interventional Treatment of Ischemic Cerebrovascular Disease", "the 2015 Symptomatic Atherosclerotic Sclerotic vertebral artery initiation stenosis: Chinese expert consensus" and "Subclavian/extracranial vertebral artery stenosis: Chinese expert consensus" in 2019 and other guidelines and expert consensus for the diagnosis of symptomatic vertebral artery atherosclerotic stenosis ≥ 50% and non-symptomatic vertebral artery atherosclerotic stenosis ≥ 70% in patients.
Treatment: The drug-eluting stent
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis in Real-World Clinical Observations: a Prospective, Multicenter, Open-access, Single-arm Clinical Study
- Plain-language title
- Tests a drug-releasing stent for narrowed vertebral arteriesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 14 March 2023